In the last set of stand-alone annual figures ahead of the completion of its acquisition by Takeda Pharmaceutical Co. Ltd. in early January, Shire PLC logged 4% growth in global product sales to $4.6bn, driven mainly by new products and neuroscience, although there were some wobbles in the hemophilia franchise, which was affected by prices and competition.
On the plus side, major approvals during the year included Takhzyro (lanadelumab-flyo), a first-in-class antibody to prevent hereditary angioedema (HAE),...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?